No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...

European shares European shares were higher on Monday as investors reacted to U.S. President Donald Trump delaying the roll ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug.

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new tab said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss ...

Copenhagen, Denmark, March 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...

Appointed Utpal Singh as Chief Scientific Officer in April 2025 to lead the next wave of differentiated and innovative medicines, building on Zealand Pharma’s strong peptide heritage and its ...

Zealand Pharma A/S ADR advanced stock charts by Barron's. View ZLDPY historical stock data and compare to other stocks, and exchanges.

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...